Illumina Q2 Earnings Call Highlights

Illumina logo

MarketBeat

Sat, August 1, 2026 at 3:03 AM GMT+3 7 min read

ILMN +0.00%

Key Points

Interested in Illumina, Inc.? Here are five stocks we like better.
Illumina exceeded expectations in Q2: Revenue rose 9.5% year over year to $1.16 billion, while non-GAAP EPS increased 10% to $1.31. The company raised its 2026 revenue outlook to $4.60 billion–$4.64 billion and EPS guidance to $5.30–$5.40.
Clinical sequencing drove growth, with clinical consumables revenue up 15% excluding China and more than 95 NovaSeq X instruments placed. The expanding installed base is expected to support future consumables demand as customers reach normalized usage.
Research markets remain pressured by funding uncertainty, with research and applied consumables expected to decline mid- to high-single digits this year. Illumina is advancing newer growth areas, including spatial biology, proteomics and its BioInsight initiative, which has added pharmaceutical partners.

GRAIL: Biotech Stock Targeting $100B Cancer Market

Illumina (NASDAQ:ILMN) raised its 2026 revenue and earnings outlook after reporting second-quarter results that exceeded its expectations, supported by clinical sequencing demand, elevated NovaSeq X placements and higher consumables volume.

Second-quarter revenue totaled $1.16 billion, up 9.5% from a year earlier, Chief Financial Officer Ankur Dhingra said. Revenue grew 6.5% organically, while rest-of-world organic revenue growth, which excludes Greater China, was 8.1%. Non-GAAP diluted earnings per share rose 10% year over year to $1.31.

→ Why SK hynix Could Be the Best AI Chip Stock to Buy Now

Strategic Buy Lights Up This Biotech Stock: Time to Invest?

"Revenue grew at the fastest rate since I joined the company," Chief Executive Officer Jacob Thaysen said, attributing the performance to increasing demand as customers expand clinical applications of Illumina's technology.

Clinical Demand Drives Consumables and Instrument Placements

Clinical markets, which represent about 65% of Illumina's sequencing consumables revenue, remained the company's principal growth driver. Sequencing consumables revenue was $775 million, up 5% year over year, with high-throughput volume contributing most of the growth as the NovaSeq X installed base expanded.

→ Microsoft Just Flipped the AI Spending Narrative Overnight

Palantir Was Left Out of the S&P 500; It Still Looks Like a Buy

Sequencing consumables revenue in clinical markets increased 15% excluding China, including growth of more than 20% in the U.S. and Canada. Thaysen said oncology continues to lead clinical adoption, while minimal residual disease, or MRD, is beginning to contribute momentum. Therapy selection remains the larger clinical oncology application by dollars, he said.

Illumina placed more than 95 NovaSeq X instruments during the quarter, as demand remained strong among clinical customers. Dhingra said the company saw several multi-unit capacity expansion orders, including orders associated with the start of new clinical trials. Illumina also placed more than 10 NovaSeq 6000 units, reflecting that some customers intend to continue using that platform for years.

→ Carrier Earnings Could Send the Stock to a New All-Time High

Sequencing instruments revenue was $125 million, up 31% year over year, driven by sales of NovaSeq X and MiSeq i100 instruments. Approximately 83% of sequencing volumes and 59% of sequencing revenue had transitioned to NovaSeq X as of the second quarter. The company expects clinical volumes to reach 80% to 85% conversion to the platform by the end of 2026.

Thaysen said the company expects the recently installed NovaSeq X base to support consumables demand over future quarters, although clinical customers typically require six to nine months to reach normalized consumables pull-through after placements.

Research Market Remains Cautious

Research and applied sequencing consumables revenue declined 7% on a rest-of-world organic basis. Dhingra said the business saw encouraging trends during the quarter, including 9% sequential revenue growth, but the company does not expect a meaningful recovery in research-market revenue during the remainder of 2026.

Management cited continued funding uncertainty among academic and research customers, though it noted increased activity later in the quarter, including more funding releases, requests and quotations in the U.S. Illumina continues to expect mid- to high-single-digit declines in research and applied consumables revenue this year.

The mix of NovaSeq X placements remained approximately 70% clinical and 30% research, according to Dhingra. Thaysen said mid-throughput instruments remain more sensitive to the macroeconomic environment because they tend to serve project-based sequencing needs, while high-throughput and low-throughput systems have remained stronger.

Multi-Omics and BioInsight Efforts Advance

Illumina also highlighted progress in its multi-omics and data initiatives. During the quarter, the company launched StrataMap Spatial, a sequencing-based spatial biology workflow, and said its newly branded SomaScan and SomaSeq proteomics offerings were generating interest following the SomaLogic acquisition.

Microarrays and other revenue rose 21% on a reported basis to $105 million, including SomaLogic revenue. On a rest-of-world organic basis, that category declined 4%.

The company's BioInsight initiative, which combines sequencing, perturbation tools, computing and artificial intelligence capabilities for biopharmaceutical customers, has begun generating revenue through its Billion Cell Atlas program. Illumina has delivered more than 300 million cells through the program and added three pharmaceutical partners after quarter-end, bringing its total to six.

Thaysen said the program is still in its early stages but is already contributing to both revenue and profit. The company said it expects new products to add one to two percentage points of growth in 2027.

Guidance Raised as Margins Hold Above Expectations

Illumina raised its full-year outlook for rest-of-world organic revenue growth to greater than 5%, from a previous range of 2% to 4%. The company lifted its reported revenue outlook by $50 million at the midpoint to a range of $4.60 billion to $4.64 billion.

Rest-of-world organic sequencing consumables growth is expected to be in the mid-single digits.
Clinical consumables growth is expected to be in the mid-teens.
Research consumables are expected to decline by the mid- to high-single digits.
Sequencing instruments are expected to grow in the low single digits organically on a rest-of-world basis.
Non-GAAP operating margin guidance was maintained at 23.4% to 23.6%.
Non-GAAP diluted EPS guidance increased to $5.30 to $5.40, up $0.12 at the midpoint from the prior outlook.

For the third quarter, Illumina forecast rest-of-world organic revenue growth of approximately 4.5%, reported revenue of $1.14 billion to $1.16 billion, non-GAAP EPS of $1.33 to $1.38 and a non-GAAP operating margin of about 24%.

Dhingra said the expected sequential margin expansion reflects a greater mix of consumables revenue, cost actions and improved efficiency. The company reported a 68.2% non-GAAP gross margin and a 22.5% non-GAAP operating margin in the second quarter, despite higher freight and memory costs.

Illumina said it secured inventory and supply for critical components for the coming quarters, helping reduce near-term exposure to memory-cost volatility. The company generated $201 million in operating cash flow and $162 million in free cash flow during the quarter. It repurchased approximately 0.9 million shares for $122 million and had about $1.8 billion remaining under its current repurchase authorizations.

About Illumina (NASDAQ:ILMN)

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company's product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

The article "Illumina Q2 Earnings Call Highlights" was originally published by MarketBeat.

View MarketBeat's top stocks for July 2026.